Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
3HP-2827 in solid tumors with FGFR2 alterations
NCT06287918Phase 1Not yet recruiting
- Sponsor
- 3H Pharmaceuticals
- Start
- Jun 2026
- Primary completion
- Mar 2028
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of 3HP-2827 in solid tumor, sponsored by 3H Pharmaceuticals. Primary endpoints: Incidence of adverse events, Incidence of dose-limiting toxicities at 28 days and 5 more. Planned start Jun 2026; status: not yet recruiting.
02
Drugs
3HP-2827
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT06287918.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06287918.